[Fibrinolysis or angioplasty in acute myocardial infarction?].
Early reperfusion during myocardial infarction limits myocardial injury and reduces mortality. Fibrinolysis (with streptokinase, or tissue or recombinant plasminogen activators) is today an established method for the treatment of myocardial infarction patients manifesting ST-segment elevation or left bundle branch block at ECG (electrocardiography), effective reperfusion being obtained in fifty per cent of cases. Extensive developments are under way, both of fibrinolytic substances and of various adjuvant treatments. A satisfactory alternative treatment to fibrinolysis is percutaneous transluminal coronary angioplasty (PTCA), a method which can be used when fibrinolysis is contraindicated or during cardiogenic shock, or when there is no sign of reperfusion in response to fibrinolytic treatment. Provided the facilities and competence are available, PTCA can even be used as primary treatment instead of fibrinolysis.
Grip
L
L
Sahlgrenska Universitetssjukhuset, Göteborg.
Hartford
M
M
D015906:Angioplasty, Balloon, Coronary; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D017408:Guidelines as Topic; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D010960:Plasminogen Activators / Q000008:administration & dosage; D011379:Prognosis; D013300:Streptokinase / Q000008:administration & dosage
D005343:Fibrinolytic Agents; D013300:Streptokinase; D010960:Plasminogen Activators